Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial
V. Wintraecken, Liesbeth Boersma, Lori M. van Roozendaal, J. de Vries, Sander M. J. van Kuijk, M. Vane, Thijs van Dalen, Jos A. van der Hage, Luc J. A. Strobbe, SC Linn, Marc B. I. Lobbes, Philip Poortmans, Vivianne C. G. Tjan‐Heijnen, K.K.B.T. van de Vijver, A. Helen Westenberg, Johannes H. W. de Wilt, Marjolein L. Smidt, Janine M. Simons
Abstract
BACKGROUND AND PURPOSE: In the BOOG 2013-08 trial (NCT02271828), cT1-2N0 breast cancer patients were randomized between breast conserving surgery with or without sentinel lymph node biopsy (SLNB) followed by whole breast radiotherapy (WBRT). While awaiting primary endpoint results (axillary recurrence rate), this study aims to perform a quality assurance analysis on protocol adherence and (incidental) axillary radiation therapy (RT) dose. MATERIALS AND METHODS: Patients were enrolled between 2015 and 2022. Data on prescribed RT and (in 25% of included patients) planning target volumes (PTV) parameters were recorded for axillary levels I-IV and compared between treatment arms. Multivariable linear regression analysis was performed to determine prognostic variables for incidental axillary RT dose. RESULTS: = 0.035, F(6, 263) = 1.532, p 0.168). CONCLUSION: The results indicate that RT-protocol adherence was high, and that incidental axillary RT dose was low in the BOOG 2013-08 trial. Potential differences between treatmentarms regarding the primary endpoint can thus not be attributed to different axillary radiation doses.